GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Cashflow Statement History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Profit Before Tax | ₹1,985 Cr | ₹1,399 Cr | ₹569 Cr | ₹868 Cr | ₹1,441 Cr |
| Adjustment | ₹2,690 Cr | ₹947 Cr | ₹1,010 Cr | ₹1,472 Cr | ₹787 Cr |
| Changes In working Capital | ₹-447 Cr | ₹-2,494 Cr | ₹-797 Cr | ₹-1,074 Cr | ₹-561 Cr |
| Cash Flow after changes in Working Capital | ₹4,228 Cr | ₹-147 Cr | ₹782 Cr | ₹1,266 Cr | ₹1,667 Cr |
| Cash Flow from Operating Activities | ₹3,445 Cr | ₹-828 Cr | ₹-265 Cr | ₹625 Cr | ₹1,109 Cr |
| Cash Flow from Investing Activities | ₹-1,283 Cr | ₹2.09 Cr | ₹4,561 Cr | ₹-528 Cr | ₹-333 Cr |
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
| Net Cash Inflow / Outflow | ₹-547 Cr | ₹-38 Cr | ₹389 Cr | ₹19 Cr | ₹255 Cr |
| Opening Cash & Cash Equivalents | ₹1,676 Cr | ₹1,658 Cr | ₹1,443 Cr | ₹1,411 Cr | ₹1,138 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | ₹0.67 Cr | - |
| Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | ₹-192 Cr | - | - |
| Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
| Effect of Foreign Exchange Fluctuations | ₹46 Cr | ₹56 Cr | ₹18 Cr | ₹12 Cr | ₹18 Cr |
| Closing Cash & Cash Equivalent | ₹1,175 Cr | ₹1,676 Cr | ₹1,658 Cr | ₹1,443 Cr | ₹1,411 Cr |
Compare Cashflow Statement of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹69,187.0 Cr | -0.2% | 10.5% | 27.4% | Stock Analytics | |
| No other companies found in this Industry | ||||||
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.2% |
10.5% |
27.4% |
| SENSEX | -1.2% |
-2.6% |
-5.2% |
You may also like the below Video Courses